

ESOP/ECOP abstract.

Practical Symposium – In-house production of CAR-T-therapy.

Jos G.W. Kosterink, Hospital pharmacist, clinical pharmacologist, professor in hospital and clinical pharmacy, University Medical Center Groningen, The Netherlands

Chimeric antigen receptor T-cell (CAR-T) therapy in particular in hemato-oncology has resulted in large progress in treatment results.

At this moment around 6 products are authorized for the different lines of therapy in the different indications (DLBCL, ALL, FL, MM, MCL) in different EU countries.

What hurdles are present and prevent broad implementation? There are also some drawbacks of commercial production.

One of the possibilities to overcome these hurdles and drawbacks is to organize in-house/point of care production.

This will be presented and discussed in this part of the session as well as a concept for broader implementation for point of care production.

We will, in this part of the session, also discuss the in-house production of CAR-T therapy. The in-house production of CAR-T cells involves a complex, multidisciplinary effort to produce, modify and reinfuse patient-specific T cells to target malignant cells. Hospital pharmacists are strongly involved and play a crucial role in the production process, quality control and quality assurance.

Besides that hospital pharmacists are involved in the optimization, improvement and innovation of the production process, the product and eventually patient outcome.

Hospital pharmacy together with other cell-therapy specialists are capable to offer a safe, even better and more affordable CAR-T therapy compared to pharmaceutical industry.